Effects of 100-km ultramarathon on erythropoietin variation in runners with hepatitis B virus carrier

Li-Hua Li; Yu-Hui Chiu; Chen Meng; Wei-Fong Kao; Chorng-Kuang How

doi:10.4103/cjp.cjp_106_20

Users Online: 622

SHORT COMMUNICATION

Year : 2021 | Volume : 64 | Issue : 3 | Page : 125-128

Effects of 100-km ultramarathon on erythropoietin variation in runners with hepatitis B virus carrier

Li-Hua Li¹, Yu-Hui Chiu², Chen Meng³, Wei-Fong Kao⁴, Chorng-Kuang How⁵
¹ Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital; PhD Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
² Department of Emergency Medicine, School of Medicine, College of Medicine, Taipei Medical University; Department of Emergency Medicine, Mackay Memorial Hospital, Taipei, Taiwan
³ Bavarian Center for Biomolecular Mass Spectrometry, Technische Universität München, Freising Deutschland, Germany
⁴ Department of Emergency Medicine, School of Medicine, College of Medicine, Taipei Medical University; Department of Emergency and Critical Care Medicine, Taipei Medical University Hospital, Taipei, Taiwan
⁵ Emergency Department, Taipei Veterans General Hospital; Department of Emergency Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

Correspondence Address:
Dr. Chorng-Kuang How
No. 201, Sec. 2, Shih-Pai Rd., Taipei 112
Taiwan

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/cjp.cjp_106_20

Completing an ultramarathon leads to an immediate postrace surge of erythropoietin (EPO). Patients with chronic liver disease may have high plasma EPO concentrations. This study aims to explore whether plasma EPO concentrations vary between hepatitis B virus carrier (HBVc) and non-HBVc runners during long distance running. Blood samples were collected from 8 HBVc and 18 non-HBVc runners at 3 different time points: 1 week before, immediately following, and then 24 h after the 100-km ultramarathon race. Samples were analyzed for plasma EPO levels. EPO concentration had a statistically significant rise immediately after the race (8.7 [7.1–11.9] mU·mL⁻¹ to 23.7 [14.8–37.2] mU·mL⁻¹, P < 0.001) and maintained the high levels 24 h after the race finished (16.7 [11.5–21.0] mU·mL⁻¹, P < 0.001) in all participants. The mean of EPO concentration was 8.9 (5.7–13.2) mU·mL⁻¹ in HBVc runners and was 8.7 (7.7–11.2) mU·mL⁻¹ in non-HBVc runners in the prerace. In HBVc runners, plasma EPO levels were no different at baseline (P = 0.657) and increased in the same fashion in response to ultramarathon compared with non-HBVc runners. Plasma EPO levels between the two groups were not statistically different at any time point. Prolonged endurance exercise led to a significant increase in EPO. A comparable increase in EPO levels was observed in HBVc and non-HBVc runners during and 24 h after 100-km ultramarathon. However, a small sample size might have affected the ability to detect a difference if it does exist.

[FULL TEXT] [PDF]*

Table of Contents

Similar in PUBMED

Search Pubmed for

Search in Google Scholar for

Related articles

Citation Manager

Access Statistics

Reader Comments

Email Alert *

Add to My List *

* Requires registration (Free)

Article Access Statistics

Viewed	2775

Printed	105

Emailed	0

PDF Downloaded	340

Comments	[Add]

Cited by others	1